Anti-adhesion molecule therapy for inflammatory bowel disease

Therapeutic Advances in Gastroenterology

Volumn 3, Issue 4, 2010, Pages 239-258

  Ghosh, Subrata ^a   Panaccione, Remo ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AJM 300; ALICAFORSEN; ALPHA4 INTEGRIN; ALPHA4 INTEGRIN ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; BETA2 INTEGRIN; BUDESONIDE; CELL ADHESION MOLECULE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; GI 270384; HYBRID PROTEIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LYMPHOTOXIN BETA RECEPTOR IMMUNOGLOBULIN FUSION PROTEIN; METHOTREXATE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1 ANTIBODY; VEDOLIZUMAB;

ALLERGIC ENCEPHALOMYELITIS; AREA UNDER THE CURVE; BLADDER CANCER; BREAST CANCER; CLINICAL TRIAL; COLITIS; COLON CANCER; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; HEADACHE; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; INFLAMMATION; INTESTINE; LIVER TOXICITY; LUNG ADENOCARCINOMA; MELANOMA; MOLECULAR THERAPY; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS CANCER;

EID: 77954179519     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X10373176     Document Type: Review

References (97)

1. Abreu, M.T. ( 2007) Crohn's disease in patients who fail infliximab therapy: what does the future hold? Rev Gastroenterol Disord 7(Suppl): S20-S26.
2. Apostolaki, M., Manoloukos, M., Roulis, M., Wurbel, M.A., Müller, W., Papadakis, K.A. et al. (2008) Role of β7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 134: 2025-2035.
3. Baert, F.J., D'Haens, G.R., Peeters, M., Hiele, M.I., Schaible, T.F., Shealy, D. et al. (1999) Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116: 22-28.
4. Baumgart, D.C. and Carding, S.R. ( 2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640.
5. Bayless, K.J., Meininger, G.A., Scholtz, J.M. and Davis, G.E. ( 1998) Osteopontin is a ligand for the α4β1 integrin. J Cell Sci 111: 1165-1174.
6. Bennett, D., Ludden, T., Shah, J., Floren, L. and Beckman, E. ( 2002) The use of pharmacokinetic (PK) modeling and efficacy data to establish optimal dosing of natalizumab (AntegrenTM). Mult Scler 8: P130 (abstract).
7. Berlin, C., Bargatze, R.F., Campbell, J.J., von Andrian, U.H., Szabo, M.C., Hasslen, S.R. et al. (1995) α4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 80: 413-422.
8. Bernklev, T., Jahnsen, J., Schulz, T., Sauar, J., Lygren, I., Henriksen, M. et al. (2005) Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol 17: 1037-1045.
9. Bernstein, C.N., Sargent, M. and Gallatin, W.M. ( 1998) β2 integrin/ICAM expression in Crohn's disease. Clin Immunol Immunopathol 86: 147-160.
10. Bevilacqua, M.P. ( 1993) Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 11: 767-804.
11. Biogen Idec and Elan Pharmaceuticals (2007 ) TYSABRI (natalizumab) Advisory Committee Briefing Document.
12. Bridges, L.C., Tani, P.H., Hanson, K.R., Roberts, C.M., Judkins, M.B. and Bowditch, R.D. ( 2002) The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin α4β1. J Biol Chem 277: 3784-3792.
13. Briskin, M., Winsor-Hines, D., Shyjan, A., Cochran, N., Bloom, S., Wilson, J. et al. (1997) Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Path 151: 97-110.
14. Burns, R.C., Rivera-Nieves, J., Moskaluk, C.A., Matsumoto, S., Cominelli, F. and Ley, K. ( 2001) Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 121: 1428-1436.
15. Campbell, J.J., Hedrick, J., Zlotnik, A., Siani, M.A., Thompson, D.A. and Butcher, E.C. ( 1998) Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279: 381-384.
16. Campbell, J.J., Qin, S., Bacon, K.B., Mackay, C.R. and Butcher, E.C. ( 1996) Biology of chemokine and classical chemoattractant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells. J Cell Biol 134: 255-266.
17. Cho, J.H. ( 2008) The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 8: 458-466.
18. Clark, M., Colombel, J.-F., Feagan, B.C., Fedorak, R.N., Hanauer, S.B., Kamm, M.A. et al. (2007) American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 133: 312-339.
19. Colombel, J.F., Sandborn, W.J., Reinisch, W., Mantzaris, G.J., Kornbluth, A., Rachmilewitz, D. et al. (2010) Infliximab, azathioprine, or combination therapy for Crohn s disease. N Engl J Med. 362: 1383-1395.
20. Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R. et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52-65.
21. Cornejo, C.J., Winn, R.K. and Harlan, J.M. ( 1997) Anti-adhesion therapy. Adv Pharmacol 39: 99-142.
22. Cosnes, J., Nion-Larmurier, I., Beaugerie, L., Afchain, P., Tiret, E. and Gendre, J.P. ( 2005) Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54: 237-241.
23. Eksteen, B., Liaskou, E. and Adams, D.H. ( 2008) Lymphocyte homing and its role in the pathogenesis of IBD. Inflamm Bowel Dis 14: 1298-1312.
24. Elan Pharmaceuticals and Biogen Idec (2010 ) TYSABRI® (natalizumab) prescribing information. South San Francisco, CA: Elan Pharmaceuticals, Inc., and Cambridge, MA: Biogen Idec Inc.
25. Farkas, S., Hornung, M., Sattler, C., Edtinger, K., Steinbauer, M., Anthuber, M. et al. (2006) Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int J Colorectal Dis 21: 71-78.
26. Feagan, B., McDonald, J.W.D. and Greenberg, G. ( 2000) An ascending dose trial of a humanized α4β7 antibody in ulcerative colitis (UC). Gastroenterology 118: A874 (abstract).
27. Feagan, B.G., Greenberg, G.R., Wild, G., Fedorak, R.N., Paré, P., McDonald, J.W. et al. (2008) Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 6: 1370-1377.
28. Feagan, B.G., Greenberg, G.R., Wild, G., Fedorak, R.N., Paré, P., McDonald, J.W. et al. (2005) Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med 352: 2499-2507.
29. Feagan, B.G., Sandborn, W.J., Hass, S., Niecko, T. and White, J. ( 2007) Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol 102: 2737-2746.
30. Ghosh, S. and Panaccione, R. ( 2007) Natalizumab maintains corticosteroid-free remission for 2 years in patients with moderately to severely active Crohn's disease and in those with prior infliximab exposure: results from an open-label extension study. Gut 56(Suppl 2): A22.
31. Ghosh, S., Goldin, E., Gordon, F.H., Malchow, H.A., Rask-Madsen, J., Rutgeerts, P. et al. (2003) Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N Engl J Med 348: 24-32.
32. Gong, Y., Barbay, J.K., Dyatkin, A.B., Miskowski, T.A., Kimball, E.S., Prouty, S.M. et al. (2006) Synthesis and biological evaluation of novel pyridazinone-based α4 integrin receptor antagonists. J Med Chem 49: 3402-3411.
33. Gordon, F.H., Lai, C.W.Y., Hamilton, M.I., Allison, M.C., Srivastava, E.D., Fouweather, M.G. et al. (2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 121: 268-274.
34. Goto, A., Arimura, Y., Shinomura, Y., Imai, K. and Hinoda, Y. ( 2006) Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis. Inflamm Bowel Dis 12: 758-765.
35. Hamamoto, N., Maemura, K., Hirata, I., Murano, M., Sasaki, S. and Katsu, K. ( 1999) Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol 117: 462-468.
36. Hamann, A., Andrew, D.P., Jablonski-Westrich, D., Holzmann, B. and Butcher, E.C. ( 1994) Role of α4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 152: 3282-3293.
37. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F. et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541-1549.
38. Hanauer, S.B., Sandborn, W.J., Rutgeerts, P., Fedorak, R.N., Lukas, M., MacIntosh, D. et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323-333.
39. Hemler, M.E., Elices, M.J., Parker, C. and Takada, Y. ( 1990) Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol Rev 114: 45-65.
40. Hesterberg, P.E., Winsor-Hines, D., Briskin, M.J., Soler-Ferran, D., Merrill, C., Mackay, C.R. et al. (1996) Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7. Gastroenterology 111: 1373-1380.
41. Hogaboam, C.M., Snider, D.P. and Collins, S.M. ( 1996) Activation of T lymphocytes by synergeneic murine intestinal smooth muscle cells. Gastroenterology 110: 1456-1466.
42. Hyams, J.S., Wilson, D.C., Thomas, A., Heuschkel, R., Mitton, S., Mitchell, B. et al. for the International Natalizumab CD 305 Trial Group (2007) Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr 44: 185-191.
43. Hynes, R.O. ( 1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25.
44. Irvine, E.J. ( 1997) Quality of life issues in patients with inflammatory bowel disease. Am J Gastroenterol 92: 18S-24S.
45. Johnson, F.R., Ozdemir, S., Mansfield, C., Hass, S., Miller, D.W., Siegel, C.A. et al. (2007) Crohn's disease patients’ risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 133: 769-779.
46. Kato, S., Hokari, R., Matsuzaki, K., Iwai, A., Kawaguchi, A., Nagao, S. et al. (2000) Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther 295: 183-189.
47. Khatri, B.O., Man, S., Giovannoni, J.C., Koo, A.P., Lee, J.C., Tucky, B. et al. (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72: 402-409.
48. Kent, S.J., Karlik, S.J., Cannon, C., Hines, D.K., Yednock, T.A., Fritz, L.C. et al. (1995) A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 58: 1-10.
49. Knowles, W.A. and Sasnauskas, K. ( 2003) Comparison of cell culture-grown JC virus (primary human fetal glial cells and the JCI cell line) and recombinant JCV VP 1 as antigen for the detection of anti-JCV antibody by haemagglutination inhibition. J Virol Methods 109: 47-54.
50. Knowles, W.A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D.W. et al. (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71: 115-123.
51. Lawrence, M.B. and Springer, T.A. ( 1991) Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell 65: 859-873.
52. Leger, O.J.P., Yednock, T.A., Tanner, L., Horner, H.C., Hines, D.K., Keen, S. et al. (1997) Humanization of a mouse antibody against human α-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 8: 3-16.
53. Lehnert, K., Print, C.G., Yang, Y. and Krissansen, G.W. ( 1998) MAdCAM-1 costimulates T cell proliferation exclusively through integrin α4β7, whereas VCAM-1 and CS-1 peptide use α4β1: Evidence for “remote” costimulation and induction of hyperresponsiveness to B 7 molecules. Eur J Immunol 28: 3605-3615.
54. Li, Z., Calzada, M.J., Sipes, J.M., Cashel, J.A., Krutzsch, H.C., Annis, D.S. et al. (2002) Interactions of thrombospondins with α4β1 integrin and CD 47 differentially modulate T cell behavior. J Cell Biol 157: 509-519.
55. Linda, H., von Heijne, A., Major, E.O., Ryschkewitsch, C., Berg, J., Olsson, T. et al. (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. New Engl J Med 361: 1081-1087.
56. Lobb, R.R. and Hemler, M.E. ( 1994) The pathophysiologic role of α4 integrins in vivo. J Clin Invest 94: 1722-1728.
57. Miles, A., Liaskou, E., Eksteen, B., Lalor, P.F. and Adams, D.H. ( 2008) CCL 25 and CCL 28 promote α4β7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow. Am J Physiol Gastrointest Liver Physiol 294: G1257-G1267.
58. Millennium Pharmaceuticals (2002) Millennium announces phase II data for MLN 02 in Crohn's disease. Millennium Investor Relations News Release, 16 September 2002. Available at: http://investor.millennium.com/phoenix.zhtml?c=80159&p=irolnewsArticle&ID=333736. Accessed 3 April 2009.
59. Millennium Pharmaceuticals (2007) Millennium resumes clinical program for MLN0002. Millennium Investor Relations News Release, 17 May 2007. Available at: http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsmediaArticle&ID=1003499&highlight=. Accessed 3 April 2009.
60. Miner Jr, P.B., Geary, R.S., Matson, J., Chuang, E., Xia, S., Baker, B.F. et al. (2006) Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 23: 1427-1434.
61. Mountain, A. and Adair, J.R. ( 1992) Engineering antibodies for therapy. Biotechnol Genet Eng Rev 10: 1-142.
62. Panaccione, R., Colombel, J.F., Enns, R., Feagan, B.G., Hanauer, S., Lawrance, I. et al. (2006) Natalizumab maintains remission for 2-years in patients with moderately to severely active Crohn's disease and in those with prior infliximab exposure: results from an open-label extension study. Abstract presented at United European Gastroenterology Week (UEGW) 2006: OP-G-180.
63. Panés, J., Aceituno, M., Gil, F., Miquel, R., Piqué, J.M., Salas, A. et al. (2007) Efficacy of an inhibitor of adhesion molecule expression (GI270384X) in the treatment of experimental colitis. Am J Physiol Gastrointest Liver Physiol 293: G739-G748.
64. Park, E.J., Mora, J.R., Carman, C.V., Chen, J., Sasaki, Y., Cheng, G. et al. (2007) Aberrant activation of integrin α4β7 suppresses lymphocyte migration to the gut. J Clin Invest 117: 2526-2538.
65. Pepio, A., Taylor, L., Koooijmans, M., Bozic, C., Quinn, G. ( 2009) Natalizumab use in patients with Crohn's disease and relapsing multiple sclerosis: updated utilization and safety results from the TOUCH TM prescribing program, the pregnancy registry, and the INFORM and TYRIS studies. Presented at: American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course; 23-28 October 2009, San Diego CA. Abstract P724.
66. Podolsky, D.K., Lobb, R., King, N., Benjamin, C.D., Pepinsky, B., Sehgal, P. et al. (1993) Attenuation of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody. J Clin Invest 92: 372-380.
67. Postigo, A.A., Teixidó, J. and Sánchez-Madrid, F. ( 1993) The α4β1/VCAM-1 adhesion pathway in physiology and disease. Res Immunol 144: 723-735.
68. Present, D., Feagan, B.G., Fedorak, R.N., Lashner, B., Panaccione, R., Rutgeerts, P. et al. (2007) Natalizumab induces sustained response and remission in Crohn's patients after previous infliximab failure: results from the ENCORE trial. Presented at: Digestive Disease Week; 19-24 May 2007, Washington, DC.
69. Richardson-Burns, S.M., Kleinschmidt-de Masters, B.K., de Biasi, R.L. and Tyler, K.L. ( 2002) Progressive multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central nervous system of patients with and without AIDS. Arch Neurol 59: 1930-1936.
70. Rivera-Nieves, J., Gorfu, G. and Ley, K. ( 2008) Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis 14: 1715-1735.
71. Sandborn, W.J., Colombel, J.F., Enns, R., Feagan, B.G., Hanauer, S.B., Lawrance, I.C. et al. for the International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group and the Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. ( 2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912-1925.
72. Sandborn, W.J., Feagan, B.G., Stoinov, S., Honiball, P.J., Rutgeerts, P., Mason, D. et al. (2007 a) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228-238.
73. Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Colombel, J.F., Panaccione, R. et al. (2007 b) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146: 829-838.
74. Sandborn, W.J. and Yednock, T.A. ( 2003) Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 98: 2372-2382.
75. Sands, B.E., Kozarek, R., Spainhour, J., Barish, C.F., Becker, S., Goldberg, L. et al. (2007) Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 13: 2-11.
76. Schreiber, S., Nikolaus, S., Malchow, H., Kruis, W., Lochs, H., Raedler, A. et al. (2001) and the German ICAM-1 Study Group. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120: 1339-1346.
77. Shanahan Jr, W.R. ( 1999) ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1. Expert Opin Investig Drugs 8: 1417-1429.
78. Soriano, A., Salas, A., Salas, A., Sans, M., Gironella, M., Elena, M. et al. (2000) VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest 80: 1541-1551.
79. Springer, T.A. ( 1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301-314.
80. Stopfer, P., Obermeier, F., Dunger, N., Falk, W., Farkas, S., Janotta, M. et al. (2004) Blocking lymphotoxin-β receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis. Clin Exp Immunol 136: 21-29.
81. Strober, W., Fuss, I.J. and Blumberg, R.S. ( 2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20: 495-549
82. Stüve, O., Marra, C.M., Cravens, P.D., Singh, M.P., Hu, W., Lovett-Racke, A. et al. (2007) Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 64: 169-176.
83. Takazoe, M., Watanabe, M., Kawaguchi, T., Matumoto, T., Oshitani, N., Hiwatashi, N., et al. (2009) Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Presented at: Digestive Disease Week; 30 May-4 June 2009, Chicago, IL. Abstract S1066.
84. Targan, S.R., Feagan, B.G., Fedorak, R.N., Lashner, B.A., Panaccione, R., Present, D.H. et al. (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132: 1672-1683.
85. van Assche, G. and Rutgeerts, P. ( 2005) Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 288: G169-G174.
86. van Deventer, S.J.H., Wedel, M.K., Baker, B.F., Xia, S., Chuang, E. and Miner Jr, P.B. ( 2006) A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 23: 1415-1425.
87. Verbeeck, J., van Assche, G., Ryding, J., Wollants, E., Rans, K., Vermeire, S. et al. (2008) JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 57: 1393-1397.
88. Vermeire, S., Abreu, M.T., D'Haens, G., Colombel, J.F., Mitchev, K., Raedler, A. et al. (2008) Assessment of certolizumab pegol in the treatment of Crohn's disease in patients for whom infliximab treatment was not successful: open-label induction preliminary results from the WELCOME study. Presented at: The Congress of European Crohn's and Colitis Organization; 28 February-1 March 2008, Lyon, France.
89. Vestweber, D. and Blanks, J.E. ( 1999) Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 79: 181-213.
90. von Adrian, U.H. and Mackay, C.R. ( 2000) T-cell function and migration. Two sides of the same coin. N Engl J Med 343: 1020-1034.
91. Wolters, F.L., Russel, M.G., Sijbrandij, J., Schouten, L.J., Odes, S., Riis, L. et al. for the European Collaborative study group on Inflammatory Bowel Disease (EC-IBD). (2006) Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 55: 510-518.
92. Yacyshyn, B., Chey, W.Y., Wedel, M.K., Yu, R.Z., Paul, D. and Chuang, E. ( 2007) A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 5: 215-220.
93. Yacyshyn, B.R., Bowen-Yacyshyn, M.B., Jewell, L., Tami, J.A., Bennett, C.F., Kisner, D.L. et al. (1998) A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114: 1133-1142.
94. Yacyshyn, B.R., Chey, W.Y., Goff, J., Salzberg, B., Baerg, R., Buchman, A.L. et al. and the ISIS 2302-CS9 Investigators ( 2002) Double blind, placebo controlled trial of the remission inducing and steroid sparring properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51: 30-36.
95. Yakubenko, V.P., Lobb, R.R., Plow, E.F. and Ugarova, T.P. ( 2000) Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon α4β1-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res 260: 73-84.
96. Yonekawa, K. and Harlan, J.M. ( 2005) Targeting leukocyte integrins in human diseases. J Leukoc Biol 77: 129-140.
97. Yousry, T.A., Major, E.O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J. et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924-933.